New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 24, 2014
06:35 EDTLLYEli Lilly still sees FY14 adjusted EPS $2.72-$2.80, consensus $2.81
Now sees FY14 reported EPS $2.70-$2.78. Sees FY14 revenue $19.4B-$20B, consensus $19.75B. . As described in the company's initial guidance, patent expirations are expected to drive a rapid and severe decline in U.S. Cymbalta and U.S. Evista sales. These revenue declines are expected to be partially offset by growth from a portfolio of other products including Humalog, TrajentaŽ, Cialis, Forteo and Alimta, as well as the animal health business. In addition, strong revenue growth is expected in China, while a weaker Japanese yen will dampen revenue growth in Japan.The company now anticipates that gross margin as a percent of revenue will be approximately 73% in 2014. Total operating expenses in 2014 are expected to decrease substantially compared to 2013. The 2014 tax rate is now expected to be approximately 19%, assuming a full-year 2014 benefit of the R&D tax credit and other tax provisions up for extension. If these items are not extended, the 2014 tax rate would be approximately 2 percentage points higher. The company now expects 2014 net income to be at least $2.9B and still expects operating cash flow to be at least $4B. Operating cash flows are still expected to be sufficient to pay the company's dividend of approximately $2.1B, allow for capital expenditures of approximately $1.3B, and fund certain business development activity and share repurchases. The company's 2014 financial guidance assumes that the acquisition of Novartis Animal Health does not close during this calendar year. Should the acquisition close during 2014, the company will revise its 2014 financial guidance, if necessary.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 4, 2015
09:20 EDTLLYARIAD drawing interest from companies besides Baxalta, dealReporter says
Subscribe for More Information
August 27, 2015
10:32 EDTLLYFDA approvals Synjardy tablets for adults with Type 2 diabetes
Subscribe for More Information
05:20 EDTLLYEli Lilly, Adocia initiate new Phase 1b study of BioChaperone Lispro
Subscribe for More Information
August 25, 2015
17:11 EDTLLYU.S. District Court rules in Eli Lilly's favor on Alimta vitamin regimen patent
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use